GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Total Stockholders Equity

ATAI (ATAI Life Sciences NV) Total Stockholders Equity : $152.05 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Total Stockholders Equity?

ATAI Life Sciences NV's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $152.05 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ATAI Life Sciences NV's Book Value per Share for the quarter that ended in Mar. 2025 was $0.86. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ATAI Life Sciences NV's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.18.

ATAI Life Sciences NV Total Stockholders Equity Historical Data

The historical data trend for ATAI Life Sciences NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Total Stockholders Equity Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial 90.82 376.91 260.74 242.96 116.30

ATAI Life Sciences NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222.54 167.89 145.72 116.30 152.05

ATAI Life Sciences NV  (NAS:ATAI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ATAI Life Sciences NV's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(152.053-0)/176.271
=0.86

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ATAI Life Sciences NV's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(14.781 + 11.887) / 152.053
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ATAI Life Sciences NV Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Total Stockholders Equity
Comparable Companies
ATXS MRVI XOMA SEPN PHAT ATYR CYDY ITOS PVLA RNAC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
9VC:Germany
Address
Wallstrasse 16, Berlin, BB, DEU, 10179
Website
https://www.atai.life
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Executives
Apeiron Investment Group Ltd. 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Srinivas Rao officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sahil Kirpekar officer: Chief Business Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Anne Nagengast Johnson officer: Chief Accounting Officer C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Florian Brand officer: See Remarks C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Stephen Bardin officer: Chief Financial Officer C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach director 158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali director 4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer director, 10 percent owner BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp 10 percent owner C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014